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Abstract
Autonomic dysfunction is frequent in patients with fibromyalgia
(FM). Heart rate variability analyses have demonstrated signs of
ongoing sympathetic hyperactivity. Catecholamines are
sympathetic neurotransmitters. Catechol-O-methyltransferase
(COMT), an enzyme, is the major catecholamine-clearing
pathway. There are several single-nucleotide polymorphisms
(SNPs) in the COMT gene associated with the different
catecholamine-clearing abilities of the COMT enzyme. These
SNPs are in linkage disequilibrium and segregate as
'haplotypes'. Healthy females with a particular COMT gene
haplotype (ACCG) producing a defective enzyme are more
sensitive to painful stimuli. The objective of our study was to
define whether women with FM, from two different countries
(Mexico and Spain), have the COMT gene haplotypes that have
been previously associated with greater sensitivity to pain. All
the individuals in the study were female. Fifty-seven Mexican
patients and 78 Spanish patients were compared with their
respective healthy control groups. All participants filled out the
Fibromyalgia Impact Questionnaire (FIQ). Six COMT SNPs
(rs2097903, rs6269, rs4633, rs4818, rs4680, and rs165599)
were genotyped from peripheral blood DNA. In Spanish
patients, there was a significant association between three
SNPs (rs6269, rs4818, and rs4680) and the presence of FM
when compared with healthy controls. Moreover, in Spanish
patients with the 'high pain sensitivity' haplotype (ACCG), the
disease, as assessed by the FIQ, was more severe. By contrast,
Mexican patients displayed only a weak association between
rs6269 and rs165599, and some FIQ subscales. In our group
of Spanish patients, there was an association between FM and
the COMT haplotype previously associated with high pain
sensitivity. This association was not observed in Mexican
patients. Studies with a larger sample size are needed in order
to verify or amend these preliminary results.
Introduction
Fibromyalgia (FM) is a frequent illness. Epidemiological stud-
ies from different parts of the world have shown a prevalence
rate of 2% to 3% in the general population. Approximately
90% of affected individuals are female [1]. The severity of the
illness diminishes the quality of life of afflicted persons [2] and
imposes a heavy economic burden on society [3]. Therefore,
FM can be considered a major health problem among contem-
porary women.
Different groups of investigators have shown that autonomic
dysfunction is frequent in patients with FM. Heart rate variabil-
ity analyses have demonstrated signs of ongoing sympathetic
hyperactivity. This hyperactivity is accompanied by a blunted
COMT = catechol-O-methyltransferase; FIQ = Fibromyalgia Impact Questionnaire; FM = fibromyalgia; HLA = human leukocyte antigen; LD = linkage 
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sympathetic response to different stressors. It has been pro-
posed that this autonomic dysfunction explains the multifac-
eted complaints of FM [4]. The defining characteristics of FM
(namely, widespread pain and allodynia) could be explained by
a pathogenesis known as 'sympathetically maintained pain'
[5].
Naturally occurring sympathetic neurotransmitters are cate-
cholamines known as norepinephrine, epinephrine, and
dopamine. All three substances act within the central nervous
system. Norepinephrine acts also in peripheral postganglionic
nerve endings and exerts local effects in close proximity to the
area where it is released, whereas epinephrine is the circulat-
ing hormone of the adrenal medulla and influences processes
throughout the body.
The major systemic transformation of catecholamines is cata-
lyzed by the catechol-O-methyltransferase (COMT) enzyme.
The COMT gene is located in region 22q11.1 to 22q11.2 of
chromosome 22. There are different single-nucleotide poly-
morphisms (SNPs) in the COMT gene which induce important
functional alterations of the enzyme. The best-studied SNP
(rs4680) occurs in codon 158 with valine-to-methionine tran-
sition (Val-158-Met). The Val-158-Val genotype gives rise to
an effective enzyme, whereas the Met-158-Met genotype pro-
duces a defective enzyme, which is incapable of effectively
clearing catecholamines from the system [6].
Zubieta and colleagues [7] demonstrated that healthy individ-
uals with the COMT Val-158-Val genotype are pain-resistant.
The opposite occurs in people with the Met-158-Met geno-
type. Gursoy and colleagues [8], of Turkey, reported an asso-
ciation between FM and the Val-158-Met COMT
polymorphism. García-Fructuoso and colleagues [9], of Spain,
described that FM patients with the Met-158-Met genotype
have a more severe form of the disease when compared with
affected individuals with the Val-158-Val genotype.
More meticulous genetic studies demonstrated that COMT
functional properties are only marginally dependent on the Val-
158-Met transition. There are other SNPs in the COMT gene
(rs6269, rs4633, and rs4818) in linkage disequilibrium (LD)
with the Val-158-Met variation. By combining these SNPs,
Diatchenko and colleagues [10] were able to identify frequent
COMT gene haplotypes strongly associated with sensitivity to
experimental pain and induction of a more defective COMT
enzyme. Healthy females with the 'high pain sensitivity haplo-
type' have a COMT enzyme 11 times less efficient than per-
sons with the 'low pain sensitivity haplotype'. Diatchenko and
colleagues [10] also demonstrated that COMT inhibition in
rats results in a dramatic increase in sensitivity to pain. Low
COMT activity may increase pain sensitivity by activating beta
(2/3)-adrenergic receptors. The objective of our investigation
was to define whether FM patients from two different countries
(Mexico and Spain) have COMT alleles associated with
increased susceptibility to pain in healthy individuals.
Materials and methods
Patients
All the subjects studied were women. The criterion for inclu-
sion was to be diagnosed with FM as per the guidelines of the
American College of Rheumatology and to be free of concur-
rent rheumatic disease. These patients were sourced from dif-
ferent private rheumatology practices in Mexico and Spain.
Mexican controls were women who considered themselves to
be healthy and who denied having chronic pain. Twenty-seven
of them were paramedical personnel and 6 were relatives of
paramedical personnel but were not related among them-
selves. Spanish controls were blood donors who denied hav-
ing chronic pain. Patients and controls were matched by
gender and age. Informed consent was obtained from all par-
ticipants, and the Human Research Committee of the National
Institute of Cardiology of Mexico approved the study.
Both patients and controls filled out a validated Spanish trans-
lation of the Fibromyalgia Impact Questionnaire (FIQ) [11].
This is an instrument designed to numerically define the overall
impact of FM across many dimensions (for example, function,
pain level, fatigue, sleep disturbance, and psychological dis-
tress) [12].
Genotyping
Genomic DNA from whole blood containing EDTA (ethylene-
diaminetetraacetic acid) was extracted by standard tech-
niques [13]. Six COMT SNPs (rs2097903, rs6269, rs4633,
rs4818, rs4680, and rs165599) were genotyped using 5' exo-
nuclease TaqMan assays on an ABI Prism 7000 Sequence
Detection System (Applied Biosystems, Foster City, CA, USA)
according to the manufacturer's instructions. The National
Center for Biotechnology Information (Bethesda, MD, USA)
SNP database was used to assign SNP numbers.
Statistical analysis
The χ2 test was used to evaluate the Hardy-Weinberg equilib-
rium for each polymorphism. Statistical analysis was carried
out with Stata 8.0 for Windows software (College Station, TX,
USA). During the exploratory analysis, our numerical data
showed a non-Gaussian distribution (Shapiro-Wilk test,
p > 0.05). Therefore, Kruskal-Wallis tests were used to com-
pare these variables. Data are presented as median and 25th
and 75th percentiles. Categorical variables were analyzed
with χ2 or Fisher tests as required and presented as absolute
frequencies and proportions. Statistical significance was set
at an alpha level of less than or equal to 0.05. The total FIQ
score was correlated with genotypes and haplotypes. Mexican
and Spanish groups were examined separately. Pairwise link-
age disequilibrium (LD, D') estimations between polymor-
phisms and haplotype reconstruction were performed with
Haploview version 3:32 (Broad Institute of MassachusettsAvailable online http://arthritis-research.com/content/9/5/R110
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Institute of Technology and Harvard University, Cambridge,
MA, USA).
Results
Table 1 shows the demographic data of the populations stud-
ied. The two groups of patients had similar age distributions
and FIQ scores. However, Mexican controls had higher FIQ
scores when compared with Spanish controls (p < 0.05).
Genotype distribution of all COMT SNPs studied in both pop-
ulations is shown in Table 2. The observed and expected fre-
quencies of the different SNPs in both populations were in
Hardy-Weinberg equilibrium. Statistically significant associa-
tions were found between three SNPs (rs6269, rs4818, and
rs4680) and the development of FM in Spaniards. In Mexi-
cans, the distribution of the six SNPs did not differ between
patients and controls.
Table 3 depicts the correlation between the SNPs and total
FIQ score. Again, there was a strong correlation between high
FIQ score and four SNP genotypes (rs6269AA, rs4633CC,
rs4818CC, and rs4680GG) in Spaniards. No correlation was
evident in Mexicans.
FIQ contains several visual analogue scales. In Spaniards,
there was an association between the above-mentioned SNPs
and the visual analogue scale scores for pain fatigue, sleep
disturbance, and morning stiffness. In Mexicans, a significant
correlation was found between rs6269 and pain and fatigue
as well as between rs165599 and disability and morning
stiffness.
LD analyses between the six SNP markers showed that four of
them – rs6269, rs4633, rs4818, and rs4680 (located in the
central region of the COMT gene) – had strong LDin both pop-
ulations. The strongest associations were found between
SNPs rs6269 with rs4680, rs6269 with rs4818, and rs4633
with rs4680 (D' = 0.986, R2 = 0.878). In light of this finding,
we analyzed the most frequent haplotypes in patients and
healthy controls to determine whether some of these haplo-
types could be associated with the risk of developing FM
among the populations in the study. There were four frequent
haplotypes in Spaniards (ACCG, ATCA, GCGG, and GTGA).
Haplotype distribution was different in Spanish patients versus
controls (p = 0.006). Patients had higher ACCG and ATCA
frequencies and a lower GTGA frequency. Mexicans had three
frequent haplotypes (ACCG, ATCA, and GCGG) that were
distributed similarly among patients and controls (Table 4). In
Spanish patients, the ACCG haplotype was strongly associ-
ated with a high-percentile FIQ score (p = 0.0001) (Table 5).
Discussion
FM strongly aggregates in families and coaggregates with
mood disorders [14]. Nevertheless, previous attempts to show
a specific genetic defect in FM yielded weak and/or divergent
results. In a multicase family study, Yunus and colleagues [15]
found a feeble association with the human leukocyte antigen
(HLA) region. The reported relationship to the serotonin trans-
porter gene (5-HTTLPR) [16] is probably linked to comorbid
depression rather than to FM itself [17]. Studies on the
dopamine D4 exon III repeat polymorphism yield inconsistent
results [18].
In view of the sympathetic dysfunction demonstrated in FM,
the COMT gene became an attractive genetic target. Explora-
tory studies by Gursoy and colleagues [8] and García-Fructu-
oso and colleagues [9] uncovered an association between the
Val-158-Met (rs4680) COMT transition and FM. In contrast,
Hagen and colleagues [19], using mail questionnaires, found
no association between Val-158-Met transition and chronic
musculoskeletal pain. Since there was no direct contact with
patients, the percentage of people with musculoskeletal pain
actually had FM was not established. Another report by the
same group using the same method described an association
between Val-158-Met polymorphism and headache [20].
In the study of Diatchenko and colleagues [10] of healthy
female volunteers, SNP rs4818 accounted for 7% of pain sen-
sitivity, SNP rs6269 for 6%, and SNP rs4680 (Val-158-Met)
showed only a marginal relationship with pain sensitivity. Our
results in the Spanish population are in line with these consid-
erations. Such SNPs were associated not only with the diag-
nosis of FM, but also with the severity of the illness as
assessed by FIQ scores. Additionally, we found SNP rs4633
to be associated with FM in Spaniards. This SNP, which rep-
resents a synonymous variation (does not produce a change
Table 1
Demographic data of the studied populations
Mexican Spanish
Patients Controls Patients Controls
Number 57 33 78 80
Mean age in years (SD) 45 (12) 45 (12) 47 (7) 44 (9)
FIQ score (SD) 70 (14) 5.9 (6.3)a 68 (11) 1.6 (2.5)a
All tested individuals were women. Mexican controls had a higher Fibromyalgia Impact Questionnaire (FIQ) score when compared with Spanish 
controls (p < 0.05) a. SD, standard deviation.Arthritis Research & Therapy    Vol 9 No 5    Vargas-Alarcón et al.
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in amino acid composition), was not found to be associated
with pain sensitivity in the study of Diatchenko and colleagues
[10].
The differences observed between Spanish and Mexican pop-
ulations were an unexpected result of our study. We view two
possible explanations for such a discrepancy.
1. Population differences. The Mexican population has been
shown to be one of the most vigorous genetic admixtures, with
genes of Caucasian, Amerindian, and African origin. A parental
group represented by Spaniards has a more homogeneous
background. Vargas-Alarcón and colleagues [21] analyzed the
HLA allele distribution in 69 populations around the world,
including Mexicans and Spaniards. Genetic distances with
corresponding analyses showed important differences
between these two groups [21]. Previously, it has been recog-
nized that, in the presence of COMT alleles, there will be eth-
nic variations. Such variations were found not only among the
general population, but also in association with disease [6].
2. Sampling error and other stratifications. Control groups
were different. Mexicans were paramedical personnel and
other women who considered themselves to be healthy. Para-
medical personnel are not the most representative of all peo-
ple without FM in the population from which the FM cases
were obtained. Mexican controls had higher FIQ scores than
their blood-donor Spanish counterparts. We consider that this
Table 2
Genotype distribution of the six catechol-O-methyltransferase single-nucleotide polymorphisms in patients and healthy controls 
from Mexico and Spain
Spanish Mexican
Genotype Patients Controls P value Patients Controls P value
n (%) n (%) n (%) n (%)
rs6269
AA 21 (27) 14 (18) 0.015a 30 (53) 17 (52) NS
AG 42 (54) 34 (42) 21 (37) 13 (39)
GG 15 (19) 32 (40) 6 (10) 3 (9)
rs4633
CC 28 (36) 19 (24) NSa 21 (37) 17 (52) NS
CT 36 (46) 37 (46) 28 (49) 13 (39)
TT 14 (18) 24 (30) 8 (14) 3 (9)
rs4818
CC 19 (24) 13 (16) 0.001 30 (53) 15 (46) NS
CG 47 (60) 33 (41) 21 (36) 12 (36)
GG 12 (16) 34 (43) 6 (11) 6 (18)
rs4680
AA 9 (12) 22 (27) 0.023a 2 (4) 4 (12) NS
AG 40 (51) 39 (49) 32 (56) 14 (42)
GG 29 (37) 19 (24) 23 (40) 15 (46)
rs20907
AA 31 (40) 23 (29) NSa 26 (46) 15 (45.5) NS
AG 34 (43) 40 (50) 24 (42) 15 (45.5)
GG 13 (17) 17 (21) 7 (12) 3 (9)
rs16559
AA 36 (46) 33 (41) NSa 12 (21) 10 (30) NSa
AG 30 (39) 35 (44) 32 (56) 15 (46)
GG 12 (15) 12 (15) 13 (23) 8 (24)
aχ2 test; NS, not significant.Available online http://arthritis-research.com/content/9/5/R110
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Table 3












AA 75.1 78.6 82.1 57.7 67.53 80.5
AG 60.6 67.1 70.1 0.0001 68.7 77.5 80.67 0.193
GG 51.1 56.3 56.7 41.01 66.77 79.17
rs4633
CC 73.9 78.7 86.1 61.4 71.25 78.17
CT 59.8 62.6 68.5 0.0001 60.7 71.29 82.7 0.785
TT 51.1 56.2 56.7 57.7 66.21 85.47
rs4818
CC 75.1 78.1 82.4 57.7 64.20 80.5
GC 60.2 65.3 70.2 0.0001 68.74 77.5 81.58 0.054
GG 51.7 56.2 61.7 60.43 66.33 73.17
rs4680
AA 50.62 52.3 56.1 57.7 72.97 88.24
AG 59.4 62.1 68.3 0.0001 62.7 74.35 83.60 0.284
GG 72.8 78.6 85 59.9 68.74 76.46
Only single-nucleotide polymorphisms with significant associations in Spaniards are shown. In Mexicans, none was associated with the 
Fibromyalgia Impact Questionnaire.
Table 4
Haplotype frequencies in patients and healthy controls from Mexico and Spain
Spanish Mexican
Patients Controls Patients Controls
(n = 78) (n = 80) (n = 57) (n = 33)
Haplotypes
ACCG 46 (0.295) 31 (0.194) 33 (0.289) 19 (0.287)
ATCA 34 (0.218) 26 (0.162) 31 (0.272) 18 (0.272)
GCGG 41 (0.263) 42 (0.262) 23 (0.201) 16 (0.242)
GTGA 24 (0.154) 52 (0.325) 0 0
Other 11 (0.070) 9 (0.056) 27 (0.236) 13 (0.197)
Total of haplotypes 156 160 114 66
P values 0.006 NS
Each frequency is calculated by dividing the occurrence of a given haplotype by the total number of haplotypes in that particular group (haplotype 
total = number of individuals × 2). NS, not significant.Arthritis Research & Therapy    Vol 9 No 5    Vargas-Alarcón et al.
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bias is unlikely to explain our diverging results. Even after the
Mexican controls with the highest FIQ score were excluded
from our calculations, differences persisted. Furthermore,
although Mexican and Spanish patients had similar FIQ
scores, they displayed a significantly different distribution in
COMT SNP rs6269, rs16559, and rs4818.
Several reports suggest that the collective grouping of SNPs
in haplotypes has a stronger association with the assessed
phenotype. In our study, COMT haplotype analysis showed a
strong association between ACCG and ATCA and the risk of
developing FM in Spanish individuals. Additionally, the ACCG
haplotype was associated with a high FIQ score in Spanish
patients. Previously, this haplotype has been designated as
'high pain sensitivity' due to the fact that healthy women with
this particular genetic make-up are much more sensitive to
painful stimuli. Our results suggest that an ACCG haplotype
could be an important susceptibility marker for FM in the Span-
ish population.
Conclusion
Our results show an association between FM and the COMT
pain sensitivity SNPs in Spaniards. By contrast, the Mexican
population displayed only a weak association between the two
SNPs and isolated FM symptoms. This phenomenon suggests
that there are population variations in susceptibility to develop-
ing FM which are related to the COMT gene polymorphism.
Studies with a larger sample size are needed in order to verify
or amend these preliminary results.
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